COMPANY
SpringWorks Therapeutics
FDA-approved therapeutic company Clinical Phase 3
SpringWorks Therapeutics, Inc is a healthcare company of Merck KGaA, Darmstadt, Germany. From company website Source · Oct 12, 2026
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Territory Business Manager - Phoenix (GOMEKLI) | Remote / Phoenix, Arizona (United States) | Oct 19, 2026 | Oct 20, 2026 |
| Territory Business Manager - Seattle (GOMEKLI) | Remote / Seattle, Washington (United States) | Oct 19, 2026 | Oct 20, 2026 |
| Territory Business Manager - New Orleans (GOMEKLI) | Remote / New Orleans, Louisiana (United States) | Sep 30, 2026 | Oct 8, 2026 |
| Regional Business Director –West Region (OGSIVEO) | Remote / (United States) | Sep 22, 2026 | Oct 8, 2026 |
| Associate Director, Payer & Access Marketing- US Rare Tumors (OGSIVEO) | Hybrid / Boston, MA (United States) | Sep 14, 2026 | Oct 8, 2026 |
Timeline
- Trial start Phase 1: A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas source ↗
- Board tracked Radar started tracking this company’s job board (7 open jobs at last check). source ↗
- Trial start Phase 1: To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants source ↗
- Trial start Phase 1: To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants source ↗
- Trial start Phase 4: Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) source ↗
- Trial start Phase 1: Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat source ↗
- Trial start Phase 2: A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF) source ↗
- Trial start Phase 1: Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib source ↗
- FDA FDA New drug/biologic (novel): GOMEKLI (mirdametinib) — NDA219389, Feb 11, 2025. Applicant at approval: SpringWorks Therapeutics, Inc. source ↗
- FDA FDA New drug/biologic (novel): GOMEKLI (mirdametinib) — NDA219379, Feb 11, 2025. Applicant at approval: SpringWorks Therapeutics, Inc. source ↗
- Trial start Phase 1: SW-682 in Advanced Solid Tumors source ↗
- Trial start Phase 1/Phase 2: Mirdametinib + BGB-3245 in Advanced Solid Tumors source ↗
- Trial start Phase 2: Nirogacestat in Ovarian Granulosa Cell Tumors source ↗
- Trial start Phase 2: MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas source ↗
- Trial start Phase 3: Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) source ↗
Upcoming milestones
- Oct 31, 2026 (ESTIMATED) · Phase 1 · Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib · NCT06997276
- Jan 18, 2027 (ESTIMATED) · Phase 1 · SW-682 in Advanced Solid Tumors · NCT06251310
- May 28, 2027 (ESTIMATED) · Phase 2 · A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF) · NCT07170644
- Feb 26, 2031 (ESTIMATED) · Phase 4 · Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) · NCT07176689
- Oct 21, 2032 (ESTIMATED) · Phase 1 · A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas · NCT07850635
Open jobs 7
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Territory Business Manager - Phoenix (GOMEKLI) | Remote / Phoenix, Arizona (United States) | Oct 19, 2026 | Oct 20, 2026 | Not stated |
| Territory Business Manager - Seattle (GOMEKLI) | Remote / Seattle, Washington (United States) | Oct 19, 2026 | Oct 20, 2026 | Not stated |
| Territory Business Manager - New Orleans (GOMEKLI) | Remote / New Orleans, Louisiana (United States) | Sep 30, 2026 | Oct 8, 2026 | Senior |
| Regional Business Director –West Region (OGSIVEO) | Remote / (United States) | Sep 22, 2026 | Oct 8, 2026 | Senior |
| Associate Director, Payer & Access Marketing- US Rare Tumors (OGSIVEO) | Hybrid / Boston, MA (United States) | Sep 14, 2026 | Oct 8, 2026 | Senior |
| Medical Science Liaison / Senior Medical Science Liaison – West Region | Remote / (United States) | Mar 31, 2026 | Oct 8, 2026 | Senior |
| Not Seeing The Job You're Looking For? | Remote | Oct 19, 2022 | Oct 8, 2026 | Mid |
Clinical trials (lead sponsor) 14
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT03962543 | MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas | Phase 2 | Active, not recruiting | Sep 29, 2019 | Sep 20, 2023 (actual) |
| NCT05041036 | Individual Patient Compassionate Use of Nirogacestat | Not listed | Available | Not listed | Not listed |
| NCT05028166 | Individual Patient Compassionate Use of Mirdametinib | Not listed | Available | Not listed | Not listed |
| NCT06251310 | SW-682 in Advanced Solid Tumors | Phase 1 | Recruiting | Jul 31, 2024 | Jan 18, 2027 (estimated) |
| NCT07850635 | A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas | Phase 1 | Not yet recruiting | Dec 10, 2026 | Oct 21, 2032 (estimated) |
| NCT06997276 | Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib | Phase 1 | Recruiting | May 7, 2025 | Oct 31, 2026 (estimated) |
| NCT07170644 | A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF) | Phase 2 | Active, not recruiting | Aug 8, 2025 | May 28, 2027 (estimated) |
| NCT07176689 | Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) | Phase 4 | Recruiting | Sep 17, 2025 | Feb 26, 2031 (estimated) |
| NCT05348356 | Nirogacestat in Ovarian Granulosa Cell Tumors | Phase 2 | Completed | Aug 30, 2022 | Jul 8, 2025 (actual) |
| NCT05580770 | Mirdametinib + BGB-3245 in Advanced Solid Tumors | Phase 1/Phase 2 | Terminated | Feb 3, 2023 | Jan 15, 2025 (actual) |
| NCT03785964 | Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) | Phase 3 | Completed | Apr 17, 2019 | Apr 7, 2022 (actual) |
| NCT07171619 | Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat | Phase 1 | Completed | Aug 21, 2025 | Nov 10, 2025 (actual) |
| NCT07279233 | To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants | Phase 1 | Completed | Dec 15, 2025 | Feb 27, 2026 (actual) |
| NCT07259330 | To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants | Phase 1 | Completed | Oct 27, 2025 | Mar 27, 2026 (actual) |
FDA records (last 2 years)
Raises and investors new
- InvestorListed in the portfolio of Bain Capital Life Sciences (captured Oct 12, 2026). portfolio page ↗
Connect
See your connections at SpringWorks Therapeutics on LinkedIn (search by name, results not checked)